Extracorporeal photopheresis for the treatment of chronic graft versus host disease

References

• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–276.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999;13:1091–1112, viii–ix.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–233.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565–2579.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Carpenter PA, Sanders JE, et al. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol. 2004;79:221–228.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Counts GW, Jr., Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011–1016.
   PubMed Web of Science ®Google Scholar
• Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2015;21:266–274.
   PubMed Web of Science ®Google Scholar
• Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23:211–234.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009;114:4919–4927.
   PubMed Web of Science ®Google Scholar
• Poe JC, Jia W, Su H, et al. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood. 2017;130:2131–2145.
   PubMedGoogle Scholar
• Hamilton BK. Updates in chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2021;2021:648–654.
   PubMedGoogle Scholar
• Markey KA, MacDonald KP, Hill GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood. 2014;124:354–362.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443–458.
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129:13–21.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129:30–37.
   PubMed Web of Science ®Google Scholar
• Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114:702–708.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol. 2011;18:414–420.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Cardones AR, Sullivan KM. How I treat refractory chronic graft-versus-host disease. Blood. 2019;133:1191–1200.
   PubMed Web of Science ®Google Scholar
• Hill L, Alousi A, Kebriaei P, et al. New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol. 2018;9:21–46.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Inamoto Y, Carpenter PA, et al. Treatment of chronic graft-versus-host disease: past, present and future. Korean J Hematol. 2011;46:153–163.
   PubMedGoogle Scholar
• Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001;97:1196–1201.
   PubMed Web of Science ®Google Scholar
• Dhir S, Slatter M, Skinner R. Recent advances in the management of graft-versus-host disease. Arch Dis Child. 2014;99:1150–1157.
   PubMed Web of Science ®Google Scholar
• Cutler CS, Koreth J, Ritz J. Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood. 2017;129:22–29.
   PubMed Web of Science ®Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243–2250.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018;2:2012–2019.
   PubMed Web of Science ®Google Scholar
• Escamilla Gomez V, Garcia-Gutierrez V, Lopez Corral L, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant. 2020;55:641–648.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385:228–238.
   PubMed Web of Science ®Google Scholar
• Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study. Blood. 2021;138:2278–2289.
   PubMed Web of Science ®Google Scholar
• Bleakley M, Sehgal A, Seropian S, et al. Naive T-cell depletion to prevent chronic graft-versus-host disease. J Clin Oncol. 2022;40:1174.
   PubMed Web of Science ®Google Scholar
• Owsianowski M, Gollnick H, Siegert W, et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant. 1994;14:845–848.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–615.
   PubMed Web of Science ®Google Scholar
• Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107:3074–3080.
   PubMed Web of Science ®Google Scholar
• Worel N, Leitner G. Clinical results of extracorporeal photopheresis. Transfus Med Hemother. 2012;39:254–262.
   PubMed Web of Science ®Google Scholar
• Greinix HT, Worel N, Just U, et al. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci. 2014;50:349–357.
   PubMed Web of Science ®Google Scholar
• Ward DM. Extracorporeal photopheresis: how, when, and why. J Clin Apher. 2011;26:276–285.
   PubMed Web of Science ®Google Scholar
• Hart JW, Shiue LH, Shpall EJ, et al. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol. 2013;4:320–334.
   PubMedGoogle Scholar
• Voss CY, Fry TJ, Coppes MJ, et al. Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis. Transfus Med Rev. 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Bruserud O, Tvedt TH, Paulsen PQ, et al. Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. Cancer Immunol Immunother. 2014;63:757–777.
   PubMed Web of Science ®Google Scholar
• Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4  +  CD25  +  GITR  +  Foxp3  +  CD62L + functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007;84:31–39.
   PubMed Web of Science ®Google Scholar
• Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112:1515–1521.
   PubMed Web of Science ®Google Scholar
• Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17:1–17.
   PubMed Web of Science ®Google Scholar
• Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J Clin Apher. 2016;31:149–162.
   PubMed Web of Science ®Google Scholar
• Malik MI, Litzow M, Hogan W, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res. 2014;49:100–106.
   PubMedGoogle Scholar
• Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003;31:459–465.
   PubMed Web of Science ®Google Scholar
• Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 2005;35:1187–1193.
   PubMed Web of Science ®Google Scholar
• Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis–results of a crossover randomized study. Biol Blood Marrow Transplant. 2011;17:1775–1782.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112:2667–2674.
   PubMed Web of Science ®Google Scholar
• Abu-Dalle I, Reljic T, Nishihori T, et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant. 2014;20:1677–1686.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Storer BE, Lee SJ, et al. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 2013;121:2340–2346.
   PubMed Web of Science ®Google Scholar
• Im A, Hakim FT, Pavletic SZ. Novel targets in the treatment of chronic graft-versus-host disease. Leukemia. 2017;31:543–554.
   PubMed Web of Science ®Google Scholar